Most cited papers from NanoCarrier (Japan)

NanoCarrier (Japan)

What are the most cited papers from NanoCarrier (Japan)?

The most cited paper from NanoCarrier (Japan) is "Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice." (Nobuhiro Nishiyama, Souichiro Okazaki, Horacio Cabral et al., 2003), with 602 citations. Next come "NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel" (563) and "Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats" (428).

Published TypeFieldAccessCitations

Showing 50 of 58 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Nobuhiro Nishiyama, Souichiro Okazaki, Horacio Cabral et al. · PubMed	15 Dec 2003	602
2	NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel Tsuyoshi Hamaguchi, Yasuhiro Matsumura, Masanobu Suzuki et al. · British Journal of Cancer Open access	22 Mar 2005	563
3	Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Hideyuki Uchino, Yasuhiro Matsumura, Takahito Negishi et al. · British Journal of Cancer Open access	Sep 2005	428
4	A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Ruth Plummer, Richard H. Wilson, Hilary Calvert et al. · British Journal of Cancer Open access	Feb 2011	386
5	Environment-Responsive Block Copolymer Micelles with a Disulfide Cross-Linked Core for Enhanced siRNA Delivery Satoru Matsumoto, R. James Christie, Nobuhiro Nishiyama et al. · Biomacromolecules	5 Dec 2008	325
6	Modeling the Onset of Symptoms of COVID-19 Joseph Larsen, Margaret R. Martin, John Daniel Martin et al. · Frontiers in Public Health Open access	13 Aug 2020	214
7	Nanomedicines: From Bench to Bedside and Beyond Henry A. Havel, Gregory L. Finch, Pamela Strode et al. · The AAPS Journal	Aug 2016	149
8	NC ‐6300, an epirubicin‐incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin Amane Takahashi, Yoshiyuki Yamamoto, Masahiro Yasunaga et al. · Cancer Science Open access	17 Mar 2013	122
9	Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown Hyun Jin Kim, Atsushi Ishii, Kanjiro Miyata et al. · Journal of Controlled Release Open access	31 Mar 2010	119
10	Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors Vivek Subbiah, Juneko E. Grilley‐Olson, Austin James Combest et al. · Clinical Cancer Research	13 Oct 2017	115
11	Tumor‐targeted chemotherapy with the nanopolymer‐based drug NC ‐6004 for oral squamous cell carcinoma Kazuhira Endo, Takayoshi Ueno, Satoru Kondo et al. · Cancer Science Open access	6 Dec 2012	111
12	Organic–inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer Yoshinori Kakizawa, Sanae Furukawa, Atushi Ishii et al. · Journal of Controlled Release Open access	Mar 2006	109
13	Improved anti‐tumor activity of stabilized anthracycline polymeric micelle formulation, NC‐6300 Mitsunori Harada, Iulian Bobe, Hiroyuki Saito et al. · Cancer Science	12 Sep 2010	99
14	Factors affecting toxicity and efficacy of polymeric nanomedicines Eiki Igarashi · Toxicology and Applied Pharmacology	22 Feb 2008	82
15	General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation Kumiko Sakai‐Kato, Nobuhiro Nishiyama, Masato Kozaki et al. · Journal of Controlled Release	13 May 2015	75
16	Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) Takasyoshi Ueno, Kazuhira Endo, Kiyomi Hori et al. · International Journal of Nanomedicine Open access	Jun 2014	67
17	Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment Theofilus A. Tockary, Saed Abbasi, Miki Matsui-Masai et al. · Proceedings of the National Academy of Sciences Open access	10 Jul 2023	55
18	Improvement of the skin penetration of hydrophobic drugs by polymeric micelles Kensuke Yotsumoto, Kenta Ishii, Miho Kokubo et al. · International Journal of Pharmaceutics	16 Oct 2018	52
19	Effect of combined treatment with the epirubicin‐incorporating micelles (NC‐6300) and 1,2‐diaminocyclohexane platinum (II)‐incorporating micelles (NC‐4016) on a human gastric cancer model Yoshiyuki Yamamoto, Ichinosuke Hyodo, Misato Takigahira et al. · International Journal of Cancer Open access	3 Dec 2013	40
20	A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma Sant P. Chawla, Sanjay Goel, Warren Allen Chow et al. · Clinical Cancer Research	7 May 2020	38
21	Enhanced antitumor effect of anti‐tissue factor antibody‐conjugated epirubicin‐incorporating micelles in xenograft models Yoshiyuki Yamamoto, Ichinosuke Hyodo, Yoshikatsu Koga et al. · Cancer Science Open access	25 Feb 2015	38
22	Remodeling tumor microenvironment with nanomedicines John Daniel Martin, Takuya Miyazaki, Horacio Cabral · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology	14 Jun 2021	36
23	OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis Noriko Yanase, Hiroko Toyota, Kikumi Hata et al. · Vaccine	6 Sep 2014	35
24	NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis Toshihiko Doi, Tetsuya Hamaguchi, Kohei Shitara et al. · Cancer Chemotherapy and Pharmacology Open access	21 Feb 2017	32
25	A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer Simona Ruxandra Volovăț, Tudor–Eliade Ciuleanu, P. Koralewski et al. · Oncotarget Open access	18 Aug 2020	30
26	Physico-chemical characterization of polymeric micelles loaded with platinum derivatives by capillary electrophoresis and related methods Farid Oukacine, Stéphane Bernard, Iulian Bobe et al. · Journal of Controlled Release	28 Sep 2014	25
27	Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs Kenji Miki, Koji Nagaoka, Mitsunori Harada et al. · International Immunopharmacology	4 Oct 2014	25
28	Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment Fotios Mpekris, Myrofora Panagi, Christina Michael et al. · Journal of Controlled Release	20 Dec 2022	24
29	Anti-Inflammatory Therapy for Temporomandibular Joint Osteoarthritis Using mRNA Medicine Encoding Interleukin-1 Receptor Antagonist Jia Deng, Yuta Fukushima, Kosuke Nozaki et al. · Pharmaceutics Open access	26 Aug 2022	23
30	Prolonged circulation and in vivo efficacy of recombinant human granulocyte colony-stimulating factor encapsulated in polymeric micelles Mitsunori Harada, Miho Ohuchi, Tatsuyuki Hayashi et al. · Journal of Controlled Release	27 Jun 2011	23
31	NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo Mitsunobu R. Kano, Harada, Iwata et al. · International Journal of Nanomedicine Open access	May 2012	19
32	Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma Richard F. Riedel, Victoria S. Chua, Ania M. Moradkhani et al. · The Oncologist Open access	3 Aug 2022	18
33	Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects Hiroki Takashima, Yoshikatsu Koga, Ryo Tsumura et al. · Journal of Controlled Release Open access	4 Apr 2020	18
34	Utility of epirubicin‐incorporating micelles tagged with anti‐tissue factor antibody clone with no anticoagulant effect Akinori Sugaya, Ichinosuke Hyodo, Yoshikatsu Koga et al. · Cancer Science Open access	17 Dec 2015	18
35	Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo Hiroko Toyota, Noriko Yanase, Takayuki Yoshimoto et al. · Oncology Reports Open access	12 Nov 2014	16
36	Phase IIa/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus Pembrolizumab in patients with head and neck cancer (HNSCC) who have failed platinum or a platinum-containing regimen Atsushi Osada, L. Mangel, Jacek Fijuth et al. · European Journal of Cancer	Oct 2020	14
37	Core–Shell Type Polystyrene Latex Possessing Reactive Poly(ethylene glycol) Brushes on the Surface for High Performance Immunodiagnostics Ryutaro Ogawa, Yukio Nagasaki, Naoya Shibata et al. · Polymer Journal	Dec 2002	9
38	Catalytic Graphitization of Wood‐Based Carbons with Alumina by Pulse Current Heating Toshimitsu Hata, Kanae Ishimaru, M. Fujisawa et al. · Fullerenes Nanotubes and Carbon Nanostructures Open access	Apr 2005	9
39	Jet injection potentiates naked mRNA SARS-CoV-2 vaccine in mice and non-human primates by adding physical stress to the skin Saed Abbasi, Miki Matsui-Masai, Fumihiko Yasui et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	27 Feb 2023	7
40	Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy Masashi Kudo, Genichiro Ishii, Naoto Gotohda et al. · Oncology Reports Open access	17 May 2022	7
41	Non-clinical, quality and environmental impact assessments of cell and gene therapy products: Report on the 5th Asia Partnership Conference of Regenerative Medicine - April 7, 2022 Toshimitsu Tanaka, Hiroshi Karasawa, Masahiko Yasumoto et al. · Cytotherapy Open access	24 Apr 2023	6
42	Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana et al. · Pharmaceutics Open access	12 Sep 2022	6
43	Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates Hiroki Matsumoto, Tadashi Watabe, Chika Igarashi et al. · Pharmaceuticals Open access	23 Sep 2021	5
44	Normalizing the Tumor Microenvironment for Radiosensitization John Daniel Martin, Rakesh K. Jain · Cancer drug discovery and develogment/Cancer drug discovery and development Book chapter	2020	5
45	Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana et al. · Pharmaceutics Open access	28 Dec 2021	4
46	Anti-VEGFR2 Antibody-modified Micelle for Triggered Drug Delivery and Effective Therapy of Choroidal Neovascularization Kei Takahashi, Tomomi Masuda, Mitsunori Harada et al. · Current Neurovascular Research	Jul 2019	4
47	Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in pts with advanced solid tumors Vivek Subbiah, Austin James Combest, J. Griley-Olsen et al. · Annals of Oncology Open access	Oct 2016	2
48	P1.03-044 Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine Lyudmila Bazhenova, Richard Tran, Juneko E. Grilley‐Olson et al. · Journal of Thoracic Oncology Open access	Nov 2017	1
49	Translational research of DDS based on polymeric micelles Takako Nishiya, Yasuhiro Matsumura, Kazunori Kataoka · Folia Pharmacologica Japonica Open access	2011	1
50	WS2 nanocarriers for cancer drug delivery: Structure, property, performance relationships and translational barriers Gabriela N Otavalo, S. Shiva Samhitha, Sofía V Sánchez et al. · Materials Today Chemistry	9 Sep 2026	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.